{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:59:28Z","timestamp":1793059168089,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515012186"],"award-info":[{"award-number":["2024A1515012186"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515010418"],"award-info":[{"award-number":["2023A1515010418"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Guangdong Provincial Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004739","name":"Chinese Academy of Sciences Youth Innovation Promotion Association","doi-asserted-by":"publisher","award":["2023372"],"award-info":[{"award-number":["2023372"]}],"id":[{"id":"10.13039\/501100004739","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110045","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:59:34Z","timestamp":1779807574000},"page":"110045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["PROTAC technology: clinical applications, future challenges, and innovative strategies"],"prefix":"10.1016","volume":"179","author":[{"given":"Fei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeshun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xishan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110045_bb0005","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cancergen.2024.06.002","article-title":"Cancer treatments: past, present, and future","volume":"286-287","author":"Sonkin","year":"2024","journal-title":"Cancer Genet."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110045_bb0010","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: an emerging therapeutic modality in precision medicine","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Cell Chem. Biol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110045_bb0015","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"14","key":"10.1016\/j.bioorg.2026.110045_bb0020","doi-asserted-by":"crossref","first-page":"14129","DOI":"10.1021\/acs.jmedchem.5c01818","article-title":"NDA submission of Vepdegestrant (ARV-471) to U.S. FDA: the beginning of a new era of PROTAC degraders","volume":"68","author":"Ma","year":"2025","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110045_bb0025","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-molecule PROTACs: new approaches to protein degradation","volume":"55","author":"Toure","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110045_bb0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110045_bb0035","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.apsb.2023.09.003","article-title":"Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies","volume":"14","author":"Peng","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110045_bb0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","article-title":"Degradation of proteins by PROTACs and other strategies","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2026.110045_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105785","article-title":"Advances in precision medicine for lupus nephritis: biomarker-and AI-driven diagnosis and treatment response prediction and targeted therapies","volume":"117","author":"Shang","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bioorg.2026.110045_bb0050","doi-asserted-by":"crossref","first-page":"1332872","DOI":"10.3389\/fmolb.2023.1332872","article-title":"Deciphering non-canonical ubiquitin signaling: biology and methodology","volume":"10","author":"van Overbeek","year":"2024","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bioorg.2026.110045_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1532878","article-title":"The role of ubiquitination and deubiquitination in urological tumours","volume":"16","author":"Gan","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110045_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.692574","article-title":"PROTAC: an effective targeted protein degradation strategy for cancer therapy","volume":"12","author":"Qi","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110045_bb0065","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"14","key":"10.1016\/j.bioorg.2026.110045_bb0070","doi-asserted-by":"crossref","first-page":"6819","DOI":"10.1021\/acs.chemrev.5c00046","article-title":"From concepts to inhibitors: a blueprint for targeting protein\u2013protein interactions","volume":"125","author":"Hong","year":"2025","journal-title":"Chem. Rev."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110045_bb0075","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s42004-025-01598-9","article-title":"Synthesis, biological evaluation and clinical trials of cereblon-based PROTACs","volume":"8","author":"Vicente","year":"2025","journal-title":"Commun. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110045_bb0080","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.scib.2024.03.056","article-title":"Targeting the undruggables\u2014the power of protein degraders","volume":"69","author":"Zhang","year":"2024","journal-title":"Sci. Bull."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110045_bb0085","doi-asserted-by":"crossref","first-page":"8281","DOI":"10.1021\/acs.jmedchem.3c00740","article-title":"Physicochemical property determinants of oral absorption for PROTAC protein degraders","volume":"66","author":"Hornberger","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110045_bb0090","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/ph17010100","article-title":"From PROTAC to TPD: advances and opportunities in targeted protein degradation","volume":"17","author":"Wang","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110045_bb0095","first-page":"409","article-title":"PROTACs targeting epigenetic proteins","volume":"2","author":"Zhang","year":"2023","journal-title":"Acta Mater. Med."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110045_bb0100","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41573-021-00199-0","article-title":"Advances in targeting \u2018undruggable\u2019transcription factors with small molecules","volume":"20","author":"Henley","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"15","key":"10.1016\/j.bioorg.2026.110045_bb0105","doi-asserted-by":"crossref","first-page":"10183","DOI":"10.1021\/acs.jmedchem.2c00691","article-title":"Targeting undruggable transcription factors with PROTACs: advances and perspectives","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110045_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.679120","article-title":"Targeting protein kinases degradation by PROTACs","volume":"9","author":"Yu","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.bioorg.2026.110045_bb0115","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-cancerbio-061824-105806","article-title":"Development of PROTAC degrader drugs for cancer","volume":"9","author":"Vetma","year":"2025","journal-title":"Annu. Rev. Cancer Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110045_bb0120","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-23-0655","article-title":"Preclinical evaluation of bavdegalutamide (ARV-110), a novel PROteolysis targeting chimera androgen receptor degrader","volume":"24","author":"Snyder","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.110045_bb0125","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.017","article-title":"Phase 1\/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Gao","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110045_bb0130","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/1078-0432.CCR-25-0471","article-title":"Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader and antagonist, for the treatment of advanced prostate cancer","volume":"32","author":"Nayak","year":"2026","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110045_bb0135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.annonc.2024.09.005","article-title":"Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Rathkopf","year":"2025","journal-title":"Ann. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.bioorg.2026.110045_bb0140","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5119","article-title":"A phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator\u2019s choice in patients with metastatic castration-resistant prostate cancer (CA071-1000 - rechARge)","volume":"43","author":"Chi","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.bioorg.2026.110045_bb0145","doi-asserted-by":"crossref","first-page":"8339","DOI":"10.1021\/acs.jmedchem.3c00136","article-title":"Targeting the estrogen receptor for the treatment of breast cancer: recent advances and challenges","volume":"66","author":"Rej","year":"2023","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.bioorg.2026.110045_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70132","article-title":"Proteolysis-targeting chimeras in cancer therapy: targeted protein degradation for next-generation treatment","volume":"131","author":"Anaya","year":"2025","journal-title":"Cancer"},{"issue":"32","key":"10.1016\/j.bioorg.2026.110045_bb0155","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1080\/14796694.2024.2377530","article-title":"VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+\/HER2- advanced breast cancer","volume":"20","author":"Hamilton","year":"2024","journal-title":"Future Oncol."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110045_bb0160","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110045_bb0165","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1021\/acs.jmedchem.3c01007","article-title":"Discovery and preclinical pharmacology of NX-2127, an orally bioavailable degrader of bruton's tyrosine kinase with immunomodulatory activity for the treatment of patients with B Cell malignancies","volume":"67","author":"Robbins","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110045_bb0170","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2022-164772","article-title":"NX-2127-001, a first-in-human trial of NX-2127, a Bruton's Tyrosine Kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies","volume":"140","author":"Mato","year":"2022","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.bioorg.2026.110045_bb0175","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1111\/bph.17332","article-title":"Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's Tyrosine Kinase-targeted protein degrader BGB-16673","volume":"181","author":"Wu","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110045_bb0180","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2024-199116","article-title":"Preliminary efficacy and safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in patients with relapsed or refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: results from the Phase 1 CaDAnCe-101 study","volume":"144","author":"Thompson","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110045_bb0185","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1182\/blood-2024-202909","article-title":"BGB-16673, a selective BTK degrader, exhibits deeper inhibition of cancer cell signaling pathways and better efficacy in MCL models","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.bioorg.2026.110045_bb0190","doi-asserted-by":"crossref","first-page":"18022","DOI":"10.1021\/acs.jmedchem.4c01305","article-title":"Discovery of KT-474 a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases","volume":"67","author":"Zheng","year":"2024","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110045_bb0195","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1038\/s41591-023-02635-7","article-title":"IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial","volume":"29","author":"Ackerman","year":"2023","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110045_bb0200","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12943-024-02024-9","article-title":"New-generation advanced PROTACs as potential therapeutic agents in cancer therapy","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110045_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108532","article-title":"Functional genomics identify distinct and overlapping genes mediating resistance to different classes of heterobifunctional degraders of oncoproteins","volume":"34","author":"Shirasaki","year":"2021","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110045_bb0210","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1021\/acs.bioconjchem.4c00253","article-title":"Targeted protein degradation (TPD) for immunotherapy: understanding proteolysis targeting chimera-driven ubiquitin-proteasome interactions","volume":"35","author":"Kamaraj","year":"2024","journal-title":"Bioconjug. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2026.110045_bb0215","doi-asserted-by":"crossref","first-page":"14271","DOI":"10.1021\/acs.jmedchem.4c03134","article-title":"Discovery of PXR antagonist MI891 and PXR degrader MI1013 and their roles in hepatic gene regulation","volume":"68","author":"Kamaraj","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110045_bb0220","article-title":"Targeted protein degradation in pancreatic cancer: advances and challenges of PROTAC-based therapeutics","volume":"165","author":"Huang","year":"2025","journal-title":"Bioconjug. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110045_bb0225","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11427-025-3111-9","article-title":"Advances in controllable targeted protein degradation: emerging strategies and mechanisms","volume":"69","author":"Ma","year":"2026","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.bioorg.2026.110045_bb0230","doi-asserted-by":"crossref","first-page":"33","DOI":"10.18632\/oncoscience.600","article-title":"Restoring our ubiquitination machinery to overcome resistance in cancer therapy","volume":"11","author":"Li","year":"2024","journal-title":"Oncoscience"},{"key":"10.1016\/j.bioorg.2026.110045_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.872729","article-title":"Overcoming cancer drug resistance utilizing PROTAC technology","volume":"10","author":"Burke","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110045_bb0240","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.3390\/molecules30102123","article-title":"PROTAC technology as a new tool for modern pharmacotherapy","volume":"30","author":"Kubry\u0144","year":"2025","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110045_bb0245","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41571-023-00815-5","article-title":"Drug-tolerant persister cells in cancer: the cutting edges and future directions","volume":"20","author":"Pu","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110045_bb0250","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/s41375-024-02365-w","article-title":"BCR:: ABL1 proteolysis-targeting chimeras (PROTACs): the new frontier in the treatment of Ph+ leukemias?","volume":"38","author":"Cruz-Rodriguez","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110045_bb0255","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-022-00999-9","article-title":"PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110045_bb0260","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: advances in drug discovery and clinical practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110045_bb0265","article-title":"Targeted protein degradation with small molecules for cancer immunotherapy","volume":"20","author":"Yang","year":"2025","journal-title":"Asian J. Pharm. Sci"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110045_bb0270","doi-asserted-by":"crossref","first-page":"8089","DOI":"10.1038\/s41467-025-63357-7","article-title":"Characterization of PROTAC specificity and endogenous protein interactomes using ProtacID","volume":"16","author":"Shrestha","year":"2025","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110045_bb0275","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41557-023-01379-8","article-title":"Proteolysis-targeting chimeras with reduced off-targets","volume":"16","author":"Nguyen","year":"2024","journal-title":"Nat. Chem."},{"issue":"40","key":"10.1016\/j.bioorg.2026.110045_bb0280","doi-asserted-by":"crossref","first-page":"18688","DOI":"10.1021\/jacs.2c08964","article-title":"Targeted protein degradation by electrophilic PROTACs that stereoselectively and site-specifically engage DCAF1","volume":"144","author":"Tao","year":"2022","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110045_bb0285","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41392-020-00245-0","article-title":"In vivo target protein degradation induced by PROTACs based on E3 ligase DCAF15","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110045_bb0290","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41589-024-01668-4","article-title":"Template-assisted covalent modification underlies activity of covalent molecular glues","volume":"20","author":"Li","year":"2024","journal-title":"Nat. Chem. Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110045_bb0295","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.chembiol.2021.01.005","article-title":"Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product function","volume":"28","author":"Luo","year":"2021","journal-title":"Cell Chem. Biol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110045_bb0300","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1021\/jacs.0c10008","article-title":"Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1","volume":"143","author":"Cotton","year":"2021","journal-title":"J. Am. Chem. Soc."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110045_bb0305","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1158\/2159-8290.CD-22-1131","article-title":"Targeted MDM2 degradation reveals a new vulnerability for p53-inactivated triple-negative breast cancer","volume":"13","author":"Adams","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.110045_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103781","article-title":"Advances in KEAP1-based PROTACs as emerging therapeutic modalities: structural basis and progress","volume":"85","author":"Chen","year":"2025","journal-title":"Redox Biol."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110045_bb0315","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.tibs.2025.07.009","article-title":"E3 ubiquitin ligases in signaling, disease, and therapeutics","volume":"50","author":"Ebadi","year":"2025","journal-title":"Trends Biochem. Sci."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110045_bb0320","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41594-025-01537-1","article-title":"Design of PROTACs utilizing the E3 ligase GID4 for targeted protein degradation","volume":"32","author":"Li","year":"2025","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110045_bb0325","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/molecules21010042","article-title":"The prodrug approach: a successful tool for improving drug solubility","volume":"21","author":"Jornada","year":"2015","journal-title":"Molecules"},{"issue":"23","key":"10.1016\/j.bioorg.2026.110045_bb0330","doi-asserted-by":"crossref","first-page":"23926","DOI":"10.1021\/acsomega.5c01241","article-title":"Prodrug strategy for PROTACs: high efficiency and low toxicity","volume":"10","author":"Li","year":"2025","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110045_bb0335","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12943-025-02404-9","article-title":"Application of photodynamic activation of prodrugs combined with phototherapy in tumor treatment","volume":"24","author":"Du","year":"2025","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.bioorg.2026.110045_bb0340","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3390\/pharmaceutics17091160","article-title":"Recent advances in the development of pro-PROTAC for selective protein degradation","volume":"17","author":"Hakem","year":"2025","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110045_bb0345","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1021\/acs.bioconjchem.3c00366","article-title":"Antibody-proteolysis targeting chimera conjugate enables selective degradation of receptor-interacting serine\/threonine-protein kinase 2 in HER2+ cell lines","volume":"34","author":"Chan","year":"2023","journal-title":"Bioconjug. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110045_bb0350","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1039\/c2cs15344k","article-title":"Targeted polymeric therapeutic nanoparticles: design, development and clinical translation","volume":"41","author":"Kamaly","year":"2012","journal-title":"Chem. Soc. Rev."},{"issue":"35","key":"10.1016\/j.bioorg.2026.110045_bb0355","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202510641","article-title":"Tandem-activatable PROTAC prodrug for tumor biomarker-driven near-infrared opto-proteolysis","volume":"64","author":"Lu","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110045_bb0360","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.7150\/thno.102531","article-title":"A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment","volume":"15","author":"Wang","year":"2025","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110045_bb0365","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41392-025-02405-6","article-title":"Reprogramming of Cancer metabolism via photoresponsive nano-PROTAC enhances pyroptosis-mediated immunotherapy","volume":"10","author":"Park","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110045_bb0370","doi-asserted-by":"crossref","first-page":"10382","DOI":"10.1038\/s41467-024-54854-2","article-title":"MMP-2-triggered, mitochondria-targeted PROTAC-PDT therapy of breast cancer and brain metastases inhibition","volume":"15","author":"Tong","year":"2024","journal-title":"Nat. Commun."},{"issue":"40","key":"10.1016\/j.bioorg.2026.110045_bb0375","doi-asserted-by":"crossref","first-page":"21860","DOI":"10.1021\/jacs.3c05948","article-title":"Selective protein of interest degradation through the split-and-mix liposome proteolysis targeting chimera approach","volume":"145","author":"Song","year":"2023","journal-title":"J. Am. Chem. Soc."},{"issue":"16","key":"10.1016\/j.bioorg.2026.110045_bb0380","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202207439","article-title":"Glutathione-scavenging nanoparticle-mediated PROTACs delivery for targeted protein degradation and amplified antitumor effects","volume":"10","author":"Liu","year":"2023","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110045_bb0385","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41392-024-01983-1","article-title":"Sequential responsive nano-protacs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600581X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600581X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T07:39:37Z","timestamp":1783150777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682600581X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":77,"alternative-id":["S004520682600581X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110045","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PROTAC technology: clinical applications, future challenges, and innovative strategies","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110045"}}